NASDAQ:CWBR

CohBar Stock Forecast, Price & News

$1.37

-0.08 (-5.52 %)

(As of 04/9/2021 07:42 PM ET)

Add

Compare

Today's Range

$1.37

Now: $1.37▼

$1.49

50-Day Range

$1.26

MA: $1.48▼

$1.93

52-Week Range

$0.85

Now: $1.37▼

$4.25

Volume610,300 shs

Average Volume697,972 shs

Market Capitalization$84.65 million

P/E RatioN/A

Dividend YieldN/A

Beta2.96

CohBar, Inc., a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. The company was founded in 2007 and is headquartered in Menlo Park, California.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CWBR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.cohbar.com

Phone650 446 7888

Employees12

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.16

Current Ratio10.26

Quick Ratio10.26

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.19 per share

Price / Book7.21

Profitability

EPS (Most Recent Fiscal Year)($0.30)

Net Income$-13,050,000.00

Net MarginsN/A

Return on Equity-124.02%

Return on Assets-80.21%

Miscellaneous

Outstanding Shares61,788,000

Market Cap$84.65 million

Next Earnings Date5/13/2021 (Estimated)

OptionableNot Optionable

Headlines

CohBar, Inc. (NASDAQ:CWBR) Given Consensus Rating of "Buy" by Brokerages
April 9, 2021 | americanbankingnews.com

CohBar (NASDAQ:CWBR) Earns "Buy" Rating from Aegis
April 6, 2021 | americanbankingnews.com

CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity - GlobeNewswire
March 31, 2021 | globenewswire.com

CohBar (NASDAQ:CWBR) PT Raised to $3.50
March 31, 2021 | americanbankingnews.com

CohBar (NASDAQ:CWBR) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS
March 31, 2021 | americanbankingnews.com

CohBar, Inc. 2020 Q4 - Results - Earnings Call Presentation
March 31, 2021 | seekingalpha.com

CohBar, Inc. (CWBR) CEO Steve Engle on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha
March 30, 2021 | seekingalpha.com

CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update - GlobeNewswire
March 30, 2021 | globenewswire.com

CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update - Yahoo Finance
March 30, 2021 | finance.yahoo.com

CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update
March 30, 2021 | finance.yahoo.com

CohBar (CWBR) Reports Complete Enrollment in Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity - StreetInsider.com
March 29, 2021 | streetinsider.com

CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity - Yahoo Finance
March 29, 2021 | finance.yahoo.com

CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
March 29, 2021 | finance.yahoo.com

CohBar (CWBR) Set to Announce Quarterly Earnings on Tuesday
March 23, 2021 | americanbankingnews.com

Aegis Initiates Coverage on CohBar (NASDAQ:CWBR)
March 22, 2021 | americanbankingnews.com

CohBar (NASDAQ:CWBR) Shares Down 8.5%
March 18, 2021 | americanbankingnews.com

CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021 - GlobeNewswire
March 16, 2021 | globenewswire.com

CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021
March 16, 2021 | finance.yahoo.com

CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases - GlobeNewswire
March 16, 2021 | globenewswire.com

CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
March 16, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.53 out of 5 stars

Medical Sector

477th out of 2,011 stocks

Pharmaceutical Preparations Industry

231st out of 772 stocks

3.5 Analyst's Opinion

Consensus Rating
CohBar has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, CohBar has a forecasted upside of 301.5% from its current price of $1.37.
Amount of Analyst Coverage
CohBar has only been the subject of 2 research reports in the past 90 days.

3.3 Community Rank

Outperform Votes
CohBar has received 8 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
CohBar has received 4 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
CohBar has received 66.67% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about CohBar and other stocks. Vote “Outperform” if you believe CWBR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CWBR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
CohBar does not currently pay a dividend.
Dividend Growth
CohBar does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CohBar insiders have not sold or bought any company stock.
Percentage Held by Insiders
39.36% of the stock of CohBar is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.20% of the stock of CohBar is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for CohBar are expected to decrease in the coming year, from ($0.24) to ($0.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CohBar is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CohBar is -4.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CohBar has a P/B Ratio of 7.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$1.37

-0.08 (-5.52 %)

(As of 04/9/2021 07:42 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CWBR News and Ratings via Email

Sign-up to receive the latest news and ratings for CWBR and its competitors with MarketBeat's FREE daily newsletter.

CohBar (NASDAQ:CWBR) Frequently Asked Questions

Is CohBar a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CohBar in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CohBar stock.
View analyst ratings for CohBar or view top-rated stocks.

What stocks does MarketBeat like better than CohBar?

Wall Street analysts have given CohBar a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CohBar wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CohBar's next earnings date?

CohBar is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for CohBar.

How were CohBar's earnings last quarter?

CohBar, Inc. (NASDAQ:CWBR) posted its quarterly earnings data on Monday, March, 29th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.02.
View CohBar's earnings history.

How has CohBar's stock price been impacted by Coronavirus?

CohBar's stock was trading at $1.76 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CWBR shares have decreased by 22.2% and is now trading at $1.37.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CWBR?

5 Wall Street analysts have issued 1-year price targets for CohBar's stock. Their forecasts range from $3.50 to $8.00. On average, they expect CohBar's stock price to reach $5.50 in the next year. This suggests a possible upside of 301.5% from the stock's current price.
View analysts' price targets for CohBar or view top-rated stocks among Wall Street analysts.

Who are CohBar's key executives?

CohBar's management team includes the following people:

Mr. Steven B. Engle M.S., CEO & Director (Age 66, Pay $424.73k)
Dr. Pinchas Cohen, Co-Founder & Independent Director (Age 64, Pay $64.12k)
Dr. Nir Yacov Barzilai, Co-Founder & Independent Director (Age 65, Pay $64.12k)
Mr. Jeffrey F. Biunno CPA, M.B.A., CPA, MBA, CFO, Treasurer & Sec. (Age 55, Pay $317.68k)
Dr. Kenneth C. Cundy, Chief Scientific Officer (Age 62, Pay $383.27k)
Dr. David Andrew Sinclair A.O., Ph.D., Co-Founder, Advisor & Consultant (Age 51)
Ms. Jordyn Tarazi, Director of Investor Relations
Dr. Changhan David Lee Ph.D., Consultant of Mitochondrial Biology
Dr. Rohit Loomba, Scientific Consultant

Who are some of CohBar's key competitors?

Some companies that are related to CohBar include Immunome (IMNM), Immunic (IMUX), Sernova (SEOVF), Arbutus Biopharma (ABUS), iBio (IBIO), ProQR Therapeutics (PRQR), VistaGen Therapeutics (VTGN), VYNE Therapeutics (VYNE), Orphazyme A/S (ORPH), TFF Pharmaceuticals (TFFP), Wave Life Sciences (WVE), CymaBay Therapeutics (CBAY), Theratechnologies (THERF), Infinity Pharmaceuticals (INFI) and Kezar Life Sciences (KZR).
View all of CWBR's competitors.

What other stocks do shareholders of CohBar own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CohBar investors own include Strongbridge Biopharma (SBBP), ZIOPHARM Oncology (ZIOP), AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu Biopharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX) and DURECT (DRRX).

What is CohBar's stock symbol?

CohBar trades on the NASDAQ under the ticker symbol "CWBR."

How do I buy shares of CohBar?

Shares of CWBR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CohBar's stock price today?

One share of CWBR stock can currently be purchased for approximately $1.37.

How much money does CohBar make?

CohBar has a market capitalization of $84.65 million. The company earns $-13,050,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does CohBar have?

CohBar employs 12 workers across the globe.

What is CohBar's official website?

The official website for CohBar is www.cohbar.com.

Where are CohBar's headquarters?

CohBar is headquartered at 1455 Adams Drive Suite 2050, Menlo Park CA, 94025.

How can I contact CohBar?

CohBar's mailing address is 1455 Adams Drive Suite 2050, Menlo Park CA, 94025. The company can be reached via phone at 650 446 7888 or via email at [email protected]

This page was last updated on 4/12/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here